Johnson & Johnson (JNJ)
| Market Cap | 555.59B +48.1% |
| Revenue (ttm) | 96.36B +5.1% |
| Net Income | 21.04B +71.1% |
| EPS | 8.64 +71.3% |
| Shares Out | 2.41B |
| PE Ratio | 26.73 |
| Forward PE | 19.57 |
| Dividend | $5.36 (2.32%) |
| Ex-Dividend Date | May 26, 2026 |
| Volume | 6,974,439 |
| Open | 231.00 |
| Previous Close | 230.42 |
| Day's Range | 229.16 - 231.76 |
| 52-Week Range | 146.12 - 251.71 |
| Beta | 0.26 |
| Analysts | Buy |
| Price Target | 243.80 (+5.63%) |
| Earnings Date | Apr 14, 2026 |
About JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription... [Read more]
Financial Performance
In 2025, Johnson & Johnson's revenue was $94.19 billion, an increase of 6.05% compared to the previous year's $88.82 billion. Earnings were $26.80 billion, an increase of 90.56%.
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price target is $243.8, which is an increase of 5.63% from the latest price.
News
Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation
More than 90% of patients surveyed who underwent bladder removal or received BCG report negative impact on most aspects of their lives Among patients treated with BCG, three- quarters describe managin...
Johnson & Johnson upgraded to Outperform from Market Perform at Leerink
Leerink analyst David Risinger upgraded Johnson & Johnson to Outperform from Market Perform with a $265 price target
Johnson & Johnson announces global launch of Shockwave C2 Aero catheter
Johnson & Johnson announced the global launch of its Shockwave C2 Aero Coronary IVL Catheter designed for improved deliverability, enhanced lesion crossing and new repositioning capabilities for the t...
Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter
SANTA CLARA, Calif.--(BUSINESS WIRE)--Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter.
Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9th, 2026. Management will participa...
Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP
Oral presentations feature CAPLYTA ® long-term data assessing relapse risk reduction in schizophrenia and new seltorexant analyses in major depressive disorder (MDD) with insomnia symptoms 18 abstract...
This Dividend Pro Likes Banks, Semi-Equipment Stocks, Altria, and J&J
Michael Barclay, lead manager of the Columbia Dividend Income fund, favors dividend growers over high yields.
Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission
Generation Fine launches after global survey finds nearly 4 in 5 patients living with major depressive disorder don't believe antidepressants will help them reach remission Campaign draws on expertise...
CVS to drop J&J's Stelara from its main formularies
CVS Health said on Tuesday it would prefer lower-cost, interchangeable biosimilars over Johnson & Johnson's psoriasis drug Stelara in its most common drug lists starting July 1.
Johnson & Johnson announces results from Phase 3 FUZION study of tremfya
Johnson & Johnson announced results from the Phase 3 FUZION study evaluating TREMFYA in adults with active perianal fistulizing Crohn’s disease. At Week 24, TREMFYA demonstrated significantly higher r...
Johnson & Johnson announces Phase 2b data from JNJ-4804 studies
Johnson & Johnson announced Phase 2b data from two studies evaluating JNJ-4804, an investigational co-antibody therapy targeting both interleukin-23 and tumor necrosis factor-alpha , in patients with ...
Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease
TREMFYA ® demonstrated significantly higher rates of combined fistula remission – complete external closure of draining fistulas and absence of fluid collection on MRI – compared to placebo at Week 24...
Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease
JNJ-4804 demonstrated highest rates of clinical and endoscopic outcomes compared to golimumab and guselkumab in patients with ulcerative colitis or Crohn's disease who have had inadequate response to ...
Johnson & Johnson announces study of OTTAVA System met primary endpoints
Johnson & Johnson announced results from the first clinical study of the investigational OTTAVA Robotic Surgical System. The results were presented at the 2026 American Society for Metabolic and Baria...
Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System
SANTA CLARA, Calif.--(BUSINESS WIRE)--Johnson & Johnson announces results from the first clinical study of the investigational OTTAVA™ Robotic Surgical System.
Johnson & Johnson’s Caplyta shows greater efficacy in major depressive disorder
Johnson & Johnson announced findings from the first network meta-analysis comparing Caplyta – lumateperone – to FDA-approved atypical antipsychotics for add-on treatment of major depressive disorder, ...
CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis
CAPLYTA ® ranked highest among FDA-approved adjunctive therapies across four measures of efficacy, based on indirect comparisons from placebo plus antidepressant therapy-controlled trials Among the se...
J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine
Spravato, the ketamine-derived nasal spray from Johnson & Johnson, was once seen as a long shot. It was difficult to deliver, heavily regulated and slow to catch on.
Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”) today announced the appointment of Ryan Koors to Vice President, Investor Relations, effective May 7, 2026. Mr. Koor...
Why These 3 Forever Stocks Belong on Your Watchlist
These companies have proved to be good stocks to buy and hold for the long term.
Johnson & Johnson to Participate in the Bernstein's 42nd Annual Strategic Decisions Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Bernstein's 42nd Annual Strategic Decisions Conference on Wednesday, May 27th, 2026. Management will participate...
J&J sees AI halving the time to generate drug development leads
Johnson & Johnson is using artificial intelligence to slash by half the time it takes to generate new leads for developing drugs, the company's chief information officer said on Monday.
FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)
Priority Review is granted to medicines that may offer significant improvements in safety or effectiveness for serious conditions like warm autoimmune hemolytic anemia, a life-threatening disease in w...
Johnson & Johnson to launch on TrumpRx with four of its prescription drugs, CBS News reports
Johnson & Johnson will start marketing four of its medications on the Trump administration's TrumpRx website on Friday, CBS News reported on Friday.
Cramer says look to these 4 stocks to go with your high-flying tech names
CNBC's Jim Cramer urged investors to look at parts of the market that have already been beaten down. He highlighted four stocks in the health-care sector as alternatives to high-flying technology and ...